CAR-T cells and stem cell transplant for blood diseases
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new approach for people with non-cancerous blood and immune system diseases. It uses your own engineered immune cells (CAR-T cells) to prepare your body for a stem cell transplant from a relative.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a non-cancerous blood or immune system disease like Fanconi anemia, congenital neutropenia, or sickle cell disease needing transfusions.
- Your heart pumps well (ejection fraction over 50%) and your oxygen level is at least 92% without extra oxygen.
- Your liver and kidney function are near normal (bilirubin, ALT, AST within safe limits).
- You do not have active serious infections (like TB, hepatitis B/C, or uncontrolled infections).
- You are not currently pregnant and agree to use birth control during and for 6 months after treatment.
- You have a suitable related donor for stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special type of stem cell transplant that removes certain cells to reduce complications. It may help people with blood diseases, immune problems, or other conditions that can be treated with a stem cell transplant.
This trial combines a special type of stem cell transplant (using half-matched donor cells) with CAR-T therapy and memory T-cell infusions for people with acute leukemia that has not responded to treatment or has come back. The goal is to provide a curative treatment for those who do not have a fully matched donor.
This trial tests a new immune cell therapy (CD7 CAR-T) given as a bridge to a stem cell transplant in people with relapsed or hard-to-treat CD7-positive leukemia. The goal is to help control the leukemia and improve chances for a successful transplant.
This trial tests giving special immune cells (CAR-T cells) that target a protein called CD19 on cancer cells, followed by a half-matched stem cell transplant, to treat high-risk blood cancers. The treatment aims to improve outcomes by using the CAR-T cells to reduce disease before the transplant.
This trial tests a special type of stem cell transplant that may help people with certain blood cancers or bone marrow diseases. The transplant uses donor stem cells that are specially selected to reduce the risk of complications. It might be an option for patients who need a transplant to treat their condition.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
Hear when a new Bone Marrow Failure Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.